Interview: Evgeniy Gaydukov – Country Director, AstraZeneca Ukraine
Evgeniy Gaydukov, Country Director of AstraZeneca Ukraine, provides insights into the remarkable growth that the…
AstraZeneca UK
Last updated: 07.09.2018
Address: London, England W1K 1LN,United Kingdom
Tel: 0207 604 8032
Web: http://www.astrazeneca.co.uk/home/
Company description
AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company. In 2013, it moved its headquarters to Cambridge, UK, and concentrated its R&D in three sites: Cambridge; Gaithersburg, Maryland, USA (location of MedImmune) for work on biopharmaceuticals; and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs.[5] AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation.[6]
The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group[7][8] (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). Since the merger it has been among the world’s largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
AstraZeneca has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. It has secondary listings on the New York Stock Exchange and the OMX exchange.
Products and services
Cardivascular medicine
Gastrointestinal medicines
Infection medicines
Oncology medicines
Neuroscience medicines
Respiratory and Inflammation medicines
Interviews
Interview with Mark Jones, Marketing Company President, AstraZeneca UK
AstraZeneca reported decrease in its global revenue for the first half of 2011 mostly due to adverse market…
Related
Amryt: A Rare Disease Startup Going Global
Formed in 2015, listed UK start-up Amryt targets rare diseases with high unmet medical need. With one commercial…
Jay Hong – President, Kukjeon, South Korea
Kukjeon, originally a leading Korean pharmaceutical wholesaler, has in recent years expanded into API…
The UK to Incentivise Big Pharma Firms to Develop New Antibiotics
In recent years, apocalyptic conversations around superbugs caused by antimicrobial resistance (AMR) have been on…
The 5 Most Influential Medical Research Charities in the UK
An unusual characteristic of the UK’s healthcare landscape is that charities fund the vast majority of…
NHS England’s Long-Term Plan to be Funded by £20.5 Billion
Today NHS England have released their long-term plan to ensure the future of the NHS and the continued care of UK…
GSK and Pfizer Consumer Health Divisions to Merge
The two Big Pharma giants today announced the merger between their consumer healthcare businesses, with the joint…
Steven Lynch – Managing Director, British Chamber of Commerce in China
Steven Lynch, managing director of the British Chamber of Commerce in China, introduces the Chamber’s activities…
Nationalism & Populism: A Roadblock for Global Pharma
Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. In his second piece for PharmaBoardroom,…
M. Sonay Gürgen – Chairman of the Board & General Manager, Selçuk…
M. Sonay Gürgen, chairman of the board and general manager of Selçuk Ecza Deposu, Turkey’s largest pharma…
The Changing Role of the Medical Rep
With more than 25 years pharmaceutical industry experience, Ian Chamberlain provides training to help pharma…
Brexit uncertainty forces AstraZeneca to freeze investment in the UK
Yesterday, pharma giant AstraZeneca announced that they have halted investment in the UK due to lack of clarity on…
The UK will add folic acid to flour to reduce defects in newborns
The UK Prime Minister has been convinced by medical professionals to fortify all flour with folic acid to reduce…
